Catalyst Pharmaceuticals (CPRX) Getting Somewhat Positive News Coverage, Study Shows

News coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has been trending somewhat positive recently, according to Alpha One Sentiment Analysis. Alpha One, a subsidiary of Accern, rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of 0.23 on Alpha One’s scale. Alpha One also assigned headlines about the biopharmaceutical company an impact score of 50 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected AlphaOne Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

CPRX has been the topic of a number of analyst reports. Roth Capital set a $3.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 20th. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Tuesday, March 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Monday, March 20th.

Shares of Catalyst Pharmaceuticals (CPRX) traded up 3.46% during midday trading on Monday, hitting $2.39. The stock had a trading volume of 692,556 shares. The company’s market cap is $200.25 million. The firm has a 50 day moving average of $2.09 and a 200-day moving average of $1.52. Catalyst Pharmaceuticals has a one year low of $0.68 and a one year high of $2.44.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). On average, analysts forecast that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-cprx-earning-somewhat-favorable-press-coverage-study-finds-updated/985263.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.